Related Experiment Video
Updated: Jan 24, 2026

Thermochemical Studies of NiII and ZnII Ternary Complexes Using Ion Mobility-Mass Spectrometry
Published on: June 8, 2022
New ternary iron(iii) aminobisphenolate hydroxyquinoline complexes as potential therapeutic agents.
Cristina P Matos1, Yasemin Yildizhan2, Zelal Adiguzel2
1Centro de Química Estrutural, Departamento de Química, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, 1049-001, Lisbon, Portugal. icorreia@tecnico.ulisboa.pt.
Two novel iron(iii) complexes show potent anticancer activity against aggressive breast and cervical cancer cells. These metallodrugs also demonstrate effectiveness against Mycobacterium tuberculosis, suggesting broad therapeutic potential.
Area of Science:
- Inorganic Chemistry
- Medicinal Chemistry
- Cancer Biology
Background:
- Development of iron-based metallodrugs for therapeutic applications is an active area of research.
- Triple-negative breast cancer (MDA-MB-231) and cervical carcinoma (HeLa) are aggressive cancers with limited treatment options.
- Hydroxyquinoline derivatives have shown promise as co-ligands in metallodrug design.
Purpose of the Study:
- To synthesize and characterize novel mixed-ligand iron(iii) complexes for potential therapeutic use.
- To evaluate the in vitro anticancer activity of these complexes against human cancer cell lines.
- To investigate the mechanism of action, including DNA interaction and apoptosis induction.
Main Methods:
- Synthesis and full characterization of two new iron(iii) complexes, [Fe(L)(8HQ)] (1) and [Fe(L)(Cl8HQ)] (2), using a tripodal aminobisphenolate ligand and hydroxyquinoline co-ligands.
- Assessment of complex stability in aqueous solution and binding affinity to Human Serum Albumin (HSA).
- In vitro cytotoxicity assays (MDA-MB-231, HeLa), apoptosis studies (morphology, DNA condensation, TUNEL), DNA damage assays (COMET), and DNA cleavage activity.
Main Results:
- Complexes 1 and 2 exhibit stability in aqueous solution and significant binding to HSA.
- Both compounds show potent, dose-dependent cytotoxicity against MDA-MB-231 and HeLa cells, outperforming the free co-ligands.
- Treatment with complexes 1 and 2 induces apoptosis, genomic damage, and ROS generation, indicating a multi-faceted mechanism of action.
Conclusions:
- The synthesized iron(iii) complexes [Fe(L)(8HQ)] (1) and [Fe(L)(Cl8HQ)] (2) are promising anticancer drug candidates in the low micromolar range.
- These complexes are particularly effective against triple-negative breast cancer cells, addressing a critical unmet medical need.
- The compounds also display significant anti-Mycobacterium tuberculosis activity, suggesting a broad spectrum of biological applications.
Related Concept Videos
Electron Transport Chain: Complex III and IV
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Formation of Complex Ions
Crystal Field Theory - Octahedral Complexes
To explain the observed behavior of transition metal complexes (such as colors), a model involving electrostatic interactions between the electrons from the ligands and the electrons in the unhybridized d orbitals of the central metal atom has been developed. This electrostatic model is crystal field theory (CFT). It helps to understand, interpret, and predict the colors, magnetic behavior, and some structures of coordination compounds of transition metals.
CFT focuses on...
Therapeutic Index
Subviral Agents

